State Street funds hold 7.3% of Idaho Strategic (IDR) in Schedule 13G

State Street Corporation and affiliated SSGA Funds Management have reported a beneficial ownership of 1,154,774 shares of Idaho Strategic Resources Inc. (IDR), representing 7.3% of the class as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The filing details shared voting power and dispositive power, consistent with pooled or advisory holdings, and does not suggest an intent to influence control of the issuer.

Original reporting
Published May 12, 2026, 3:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 12, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$IDR
Neutral
high confidence
Mentioned
$IDR
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$IDRNeutralLow
01

Why it matters

This passive ownership does not directly influence company operations or stock price in the short term.

02

Market read

The disclosure is primarily relevant for institutional investors and analysts monitoring ownership structures; limited immediate trading impact.

03

What to watch

The passive nature of the ownership change suggests limited influence on company fundamentals; other factors such as market conditions and company performance should be considered for trading decisions.

Relevance 6/10Timing: low

Background

The filing indicates that State Street and affiliated funds have increased their passive holdings in IDR, reflecting institutional interest without active control.

Company-level read

Ticker impact

$IDRNeutralHigh confidence
Context

Passive institutional ownership reported via Schedule 13G, indicating no immediate influence on company control.

Expected impact

Minimal short-term price movement expected due to passive nature of ownership change.

Evidence & confidence

Passive filings typically reflect institutional holdings without immediate trading implications; no active buy or sell signals are indicated.

Market effects

Limited; no direct impact on the sector based on passive ownership disclosure.

Minimal; no regional effects anticipated.

Low; the filing pertains to a specific company with no broader global implications.

Counterpoint

Some traders might interpret increased institutional holdings as a positive signal for future stability or growth, suggesting potential for long-term appreciation.

Key entities

  • State Street Corporation

    A major financial services company reporting passive ownership in IDR.

  • Idaho Strategic Resources Inc.

    The subject company of the ownership disclosure.

Related articles

$IDRMed

Idaho Strategic Resources Reports Significant Concentrations of Heavy Rare Earth Elements, Including Yttrium at Its Diamond Creek Project

Idaho Strategic Resources (NYSE American: IDR) reported heavy rare earth element and yttrium mineralization at its Diamond Creek project. Surface sampling across four prospects along a 3.2 km lineament averaged about 1.8% TREO with HREO above 2,000 ppm, including over 1,300 ppm yttrium. The Lucky Gem trench averaged 1.5% TREO with ~1,600 ppm yttrium, and drillhole DC 22-8 intersected 11.3 m at 1.5% TREO with ~1,700 ppm yttrium. IDR plans further studies and 2026 exploration.

Med

Silverco Mining Ltd.: Silverco Mining Ships First Cusi Concentrate, Provides Cusi Restart Update

Silverco Mining (TSXV: SICO) shipped its first concentrate from the Cusi Property in Mexico, on schedule and within budget. The company aims to ramp up production to 1,200 tonnes per day by H1 2027 and expects over 4 million ounces of silver equivalent production in 2027 from Cusi and La Negra. CEO Mark Ayranto highlighted the milestone as a significant catalyst for the company.

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$SHAZMed

What SharonAI (SHAZ) Said on Its Q3 Earnings Call

SharonAI (SHAZ) reported Q3 earnings, highlighting a $1.32B agreement and new contracts totaling $1.17B. The company terminated a $373M contract due to credit risk. CFO Anuj Goel noted $2.6B in capital secured since December 2025, with $1.3B in cash as of Sept. 30. The NVIDIA AICP program covers 72MW and 40,000 GPUs, with billing expected from Q3 2027. SharonAI plans to fund build-out with secured debt and expects $800M in customer deposits.